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The term carcinoid, karzinoid (carcinomaslike), was first mentioned in the literature in 1907 by Oberndorfer.1 Since its recognition as a 
distinct entity it has been quite a controversial tumor, 
especially with respect to its biological behavior. In fact, 
although traditionally considered a benign neoplasm, 
distant metastases and tumorsrelated deaths were very 
soon sporadically recorded.1 
Carcinoids are exceedingly rare neoplasms in the 
middle ear2 and are usually referred to as adenoma/
carcinoid tumors because they are considered benign 
glandsforming neoplasms with an overt tendency to des
velop neuroendocrine and mucinous differentiations.3,4
Most literature reviews and textbooks on pathology 
highlight the benign clinical course of this entity. Some 
authors, however, have reported in recent years both los
cal recurrences and extracranial lymph node metastases 
in the neck.5s8 Interestingly, no visceral metastases have 
been reported so far.9 The case reported here represents 
a unique example of middle ear carcinoid with regional 
lymph node and liver metastasis that led to the patient’s 
death after 11 years of follow up.
CASE
A right middle ear tumor was discovered on otoscopy 
in 45syearsold man who consulted for hypoacusis. On 
physical examination, the tumor occupied mainly the 
middle ear, but extended to the external auditory chans
nel. CT scans showed an increased density in the mids
dle ear that was initially interpreted as cholesteatoma. 
A tympanoplastia was performed and the obtained mas
terial was diagnosed as middle ear adenoma/carcinoid 
tumor with positive surgical margins. The patient was 
then treated with radiotherapy.
Three years later, the patient consulted for otorrhea, 
otalgia, hypoacusis, and blockage of the temporomans
dibular joint. A retrotympanic mass was seen on otoss
copy. CT scan showed a middle ear tumor eroding the 
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cranial bone (Figure 1A). The tumor was surgically exs
cised. Five years later, the tumor again recurred. MRI 
showed the middle ear mass destroying the temporal 
petrous bone with intracranial extension (Figure 1B). 
Temporosparietal craniotomy with partial tumor resecs
tion and radiotherapy was performed.
One year later, the patient remained symptomatic 
and was sent for consultation to another institution. 
Lymph node metastases were detected on CT scans 
(Figure 1C). A right petrosectomy and regional lymphs
adenectomy were performed there. The same histos
pathological diagnosis was made at that time.
One year later, the patient consulted again in our 
institution because of a new tumor recurrence. MRI 
showed a 12 cm in diameter tumor mass at the region 
invading the medium cranial fossa with compressive 
signs into the adjacent cerebral tissue. OcteotridesIn111 
gammagraphy and a CT scan (Figure 1D) additionally 
revealed liver metastases which were histologically cons
firmed with core biopsy. The patient then received ches
motherapy with carboplatin plus VP16, but died of the 
disease 5 months later. The evolution since the initial 
diagnosis to death was 11 years.
Pathological findings
Grossly, the specimens at the first resection consisted of 
multiple and irregular fragments of hemorrhagic tumor 
tissue (Figure 2). Subsequent surgical procedures in our 
institution also included bone and cerebral tissue. Of 
note, the primary tumor, all recurrences, the lymph node 
metastasis, and the liver mass all showed the same basic 
histology. Tumour cells were arranged in nests, ribbons, 
cords, and acini lying in a fibrous vascularsrich stroma, 
and showed a monotonous appearance with polygonal 
shape, eosinophilic granular cytoplasm, and regular nus
clei without nucleoli (Figures 3A, 3B). The successive 
recurrences and metastases did not display significant 
changes in the tumor morphology. Atypia, mitoses, 
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Figure	1.	(a) CT scan showing a tumor 
occluding the external auditory channel 
and occupying the middle ear. (B) CT scan 
showing the intracranial tumor extension. 
(C) CT scan showing a nodal tumor mass 
in the neck. (D) CT scan demonstrating 
liver metastasis.
Figure	2.	macroscopic view of the 
tumor specimens showing irregular 
hemorrhagic fragments.
Figure	3.	(a) microscopic view of 
the tumor showing two components, 
endocrine and adenomatous, lying in 
a hemorrhagic stroma (H&e ×100). (B) 
microscopic detail of the endocrineb
appearing area with cords and ribbons 
of deep eosinophilic cells with no atypia 
nor mitosis (H&e ×250). (C) Focal intense 
immunostaining with chromogranin 
a in the tumor cells (chromogranin a, 
hematoxylin counterstaining, ×250) (D) 
Diffuse synaptophysin immunostaining 
in the tumor cells (synaptophysin, 
hematoxylin counterstaining, ×250).
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necrosis, and angioinvasion were not seen. One of the 
recurrences showed direct invasion into the cerebral tiss
sue. The lymph node metastasis displayed extracapsular 
extension of the tumor. The tumor cells showed positive 
immunostaining with chromogranin (Figure 3C), syns
aptophysin (Figure 3D) and CD56 in many areas. Ki67 
showed nuclear positivity in <20% of tumor cells.
DISCUSSIOn
The carcinoid tumor was first described in the middle 
ear by Murphy et al in 198010 and ever since experts in 
the field have been engaged in a permanent debate: do 
this tumor and the previously described middle ear ads
enoma11 represent the same entity? The current WHO 
classification,4 a recent review of these tumors,2 and the 
hitherto largest published series3 all favor the opinion 
that the adenoma and carcinoid tumor in the middle ear 
represent two faces of the same coin. The synonymy of 
various terms has contributed to the confusion. Torske 
and Thompson3 proposed the term neuroendocrine ads
enoma of the middle ear in their series of 48 cases, and 
Michaels and Soucek,4 in the 2005 WHO classification 
edition, defined this tumor as a benign glandular neos
plasm with a variable tendency towards neuroendocrine 
and mucous differentiations. They accepted adenomas
toid tumor, neuroendocrine adenoma, and middle ear 
carcinoid as synonyms. When compared with other 
head and neck territories, i.e. the larynx, the confusion 
still remains. Here, carcinoid tumor, atypical carcinoid 
tumor, and poorly differentiated neuroendocrine cars
cinoma are related entities with very different clinical 
behavior that are distinguished exclusively on the basis 
of their histological characteristics.
Wherever they arise, carcinoid tumors are wellsdes
fined neoplasms. They show very few or no nucleoli, 
very scarce (less than 2/10 HPF) or no mitosis, and 
no necrosis, nuclear pleomorphism, nor angioinvasion. 
Despite the fact that all carcinoids share a common 
histology, the clinical behavior is quite different and des
pends, for example, on the primary site of origin.
Middle ear carcinoids usually pursue an indolent 
clinical course. However, local recurrences and regional 
lymph node metastases have occasionally been reports
ed. Mooney et al,5 Menezes and Wakely,6 and Pellini et 
al7 all reported isolated cases of middle ear carcinoid 
tumor with recurrences and locosregional lymph node 
metastases. The AFIP series reports 8 recurrences after 
surgery in a total of 48 patients (16.6%), but no tumors
related death.3 Ramsey et al,8 in a recent paper adding 4 
cases to a literature review, identify a total of 22% of local 
recurrences and 9% of regional lymph node metastases. 
Michaels and Soucek mention in the last WHO book 
on head and neck tumors that “there have been a few 
recurrences after incomplete local surgical resection”.4 
Finally, Ferlito et al9 claim to consider this entity as a 
lowsgrade and slow growing tumor with some capacity 
for regional lymphatic dissemination. In addition, they 
specifically state that “to date, distant metastases have 
not been associated with middle ear carcinoid tumors”.9
Laryngeal carcinoids, however, behave much more 
aggressively, with 33% of the reported cases developing 
distant metastases to the liver and bone.12 A critical res
view applying strict histological criteria probably would 
reclassify some of them as atypical carcinoids.13 In addis
tion, Soga et al14 emphasized the unpredictability of its 
biological behavior.
Apart from the presence of adjacent tissue invasion 
or metastases, there are no reliable markers for evalus
ating the biological aggressiveness of these neuroendos
crine neoplasms.15 A proliferative index >2% (Ki67) 
may predict the malignant potential, but immunostains
ing is usually focal and may not appear in the first diags
nostic biopsy. On the other hand, it is difficult to apply 
the histological criteria of laryngeal atypical carcinoid to 
middle ear carcinoid tumor because this entity has not 
yet been described in this topography.4
The diagnosis of carcinoid tumor relies on the idens
tification of conventional neuroendocrine markers in 
an otherwise histologically typical tumor. A multihors
monal production capacity has been described in these 
cases.16 The differential diagnosis includes paragans
gliomas, negative with cytokeratins; ceruminomas, a 
double cell layer with apocrine changes in luminal cells, 
and Schneiderianstype papillary tumors of the region. 
A metastatic seed from carcinoid tumors of the gut or 
even an amelanotic melanoma should also been ruled 
out.17
To conclude, we report the first documented case of 
middle ear carcinoid tumor with distant metastases and 
tumorsrelated death after 11 years of follow up. Despite 
these rare tumors having been considered to date as low 
aggressive neoplasms, we advise a longsterm follow up 
to ascertain its supposed benignity. The term atypical 
carcinoid tumor could be applied in these specific cases 
with proven aggressive behavior. We propose in these 
tumors the adoption of the same grading system based 
in mitotic index and Kis67 index recently applied to 
foregut neuroendocrine tumors.18
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